BeiGene’s aggressive expansion brings revenue jolt
The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year Key…
Recent Articles
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US
6160.HK
688235.SHG
RECENT ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Cango gets crypto jolt back to revenue growth, profitability
CANG.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Blue Moon shadowed by aggressive promotional spending in slowing economy
6993.HK
